Literature DB >> 1415419

A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term.

B M Sibai1, J R Barton, S Akl, C Sarinoglu, B M Mercer.   

Abstract

OBJECTIVE: The objective of our study was to test the hypothesis that treatment with nifedipine for mild preeclampsia remote from term reduces the number of days of maternal hospitalization and improves pregnancy outcome. STUDY
DESIGN: A total of 200 patients at 26 to 36 weeks' gestation were randomly allocated to treatment with either bed rest alone (n = 100) or bed rest in combination with nifedipine (n = 100).
RESULTS: Patients receiving nifedipine had significantly lower systolic (p < 0.0001) and diastolic (p < 0.0001) blood pressures during therapy. Severe hypertension as an indication for delivery was significantly (p < 0.05) more frequent in the bed-rest-alone group. The two study groups had similar average days of maternal hospitalization (12.6 +/- 7.9 vs 12.3 +/- 10.3) and pregnancy prolongation (22.3 +/- 13.5 vs 22.5 +/- 15.7). There were no differences between groups with respect to birth weight, incidences of small-for-gestational-age infants and preterm birth, number of days spent in special care unit, or cord blood gas measurement.
CONCLUSION: Nifedipine therapy for preeclampsia reduces maternal blood pressure but does not reduce number of days of maternal hospitalization or improve perinatal outcome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415419     DOI: 10.1016/s0002-9378(12)80005-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  16 in total

1.  [Heart diseases in pregnancy].

Authors:  Vera Regitz-Zagrosek; Christa Gohlke-Bärwolf; Annette Geibel-Zehender; Markus Haass; Harald Kaemmerer; Irmtraut Kruck; Christoph Nienaber
Journal:  Clin Res Cardiol       Date:  2008-09       Impact factor: 5.460

2.  Society for Maternal-Fetal Medicine Consult Series #50: The role of activity restriction in obstetric management: (Replaces Consult Number 33, August 2014).

Authors:  Jhenette Lauder; Anthony Sciscione; Joseph Biggio; Sarah Osmundson
Journal:  Am J Obstet Gynecol       Date:  2020-04-29       Impact factor: 8.661

3.  A polypeptide drug carrier for maternal delivery and prevention of fetal exposure.

Authors:  Eric M George; Huiling Liu; Grant G Robinson; Gene L Bidwell
Journal:  J Drug Target       Date:  2014-08-22       Impact factor: 5.121

Review 4.  The management of pregnancy in hypertensive patients.

Authors:  R D Tunbridge
Journal:  Postgrad Med J       Date:  1994-11       Impact factor: 2.401

Review 5.  Treating hypertension in women of child-bearing age and during pregnancy.

Authors:  L A Magee
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 7.  Hypertension in pregnancy: a review of therapeutic options.

Authors:  D Kernaghan; A C Duncan; G A McKay
Journal:  Obstet Med       Date:  2012-02-17

Review 8.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

Authors:  E Rey; J LeLorier; E Burgess; I R Lange; L Leduc
Journal:  CMAJ       Date:  1997-11-01       Impact factor: 8.262

Review 9.  [Hypertensive diseases in pregnancy].

Authors:  V Thäle; A Schlitt
Journal:  Internist (Berl)       Date:  2008-07       Impact factor: 0.743

10.  What is the best drug to prescribe for a young woman in her childbearing years with essential hypertension?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.